Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $136 to $132.
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $136 to $132.